Acumen Pharmaceuticals successfully combines Cellomics™ fluorescence microscopic imaging system with MDL® Assay Explorer® and other MDL applications to manage high content screening data and image based assays. (Molecular Connection Vol 24 No 4, 2006)

The GeneGo databases, MetaCore™ and MetaDrug™, are now integrated with the DiscoveryGate® platform. This collaboration enables researchers to identify drug targets and bioactive compounds via pathway analysis and retrieve comprehensive information on their synthesis, biological effects and commercial availability without having to re-query for it. (Molecular Connection Vol 24 No 4, 2006)

Recordati, an independent pharmaceutical company based in Milan, Italy, has begun migrating its informatics system for drug discovery and preclinical development from MDL® ISIS to the open, flexible and scalable MDL® Isentris® system. (Molecular Connection Vol 24 No 3, 2006)

The National Institutes of Health (NIH) freely available PubChem database of small molecule data is now integrated with the DiscoveryGate® platform. This collaboration extends the scope of available content, and will help researchers find critical information while avoiding unnecessary, repetitious searches of multiple systems or data sources. (Molecular Connection Vol 24 No 2, 2006)

Chinese researchers screened the MDL® Comprehensive Medicinal Chemistry (CMC) database for candidates using a virtual screening strategy to find potential binding molecules for one of the most promising targets for anti-SARS-CoV drugs. (Molecular Connection Vol 24 No 1, 2006)

MDL Assay Explorer anchors suite of MDL products used to screen renal cell carcinoma cell lines at Stanford's new High-Throughput Biosciences Center. (Molecular Connection Vol 23 No 3, Summer 2005, pp 3-5)

Intervet builds custom registration system on MDL Isentris technology. (Molecular Connection Vol 23 No 1, Winter 2005, pp 4-5)

Liver toxicity is a common cause of failure in new drug development. A system for predictive hepatotoxicology for use in the design of new screening campaigns and optimizing leads could dramatically reduce the time and cost of drug development. Together, MDL and Amphioxus Cell Technologies are creating a large database of compounds tested in a variety of toxicity assays that will provide a framework in which to examine the structural basis of liver toxicity.

Abbott Labs implements a Therapeutic Area Database, standardizing data-handling systems across its worldwide research groups (Drug Discovery & Development, December 2003)

Could any of these compounds have adverse effects? Identify promising compounds early with MDL Discovery Predictive Science solutions.

Spending too much time planning, tracking, and analyzing your syntheses? Simplify your workflow with MDL Discovery Chemistry workflow solutions.

Which "active" in your assay is the best lead candidate? Support your decision with MDL Discovery Biology workflow solutions.

Web site expands to offer tips and tools to researchers and administrators. (Molecular Connection Vol. 20 No. 3, Fall 2002, pp 10-11)

The next-generation in chemical drawing has arrived, giving scientists and developers cause to celebrate. (Molecular Connection Vol. 20 No. 3, Fall 2002, p 16)

Absorption, distribution, metabolism, excretion, and toxicity (ADMET) are critical properties studied in drug discovery and design. More than 60% of all compounds fail in development and clinical trials because of adverse ADMET characteristics. Fortunately, with higher throughput assays, more observed data, and better predictive models, researchers can now assess ADMET properties earlier in the discovery process, potentially reaping substantial savings in research time and costs. (Molecular Connection Vol 20 No 2, Summer 2002, pp 12-14)

The Aventis team established a guiding principle early in the project: The new system should conform to the scientific workflow, not the confines of software or technology. The result was consistent, high-quality data at sites worldwide, and integrated access to a global network of information. (Molecular Connection Vol 20 No 2, Summer 2002, pp 8-9)

This study illustrates the use of MDL® Available Chemicals Directory (ACD) and DOCK for rational drug design at Jefferson Medical College's Peptide Chemistry Laboratory. (Molecular Connection Vol. 19 No. 1, Spring 2000, pp 10-11)

See how easy it is to create ad hoc and regularly scheduled multi-sectioned reports, including structures and data from Oracle and MDL databases. (Molecular Connection Vol. 20 No. 1, Spring 2002, pp 10-11)

Prioritizing new syntheses with Metabolite by assessing likely metabolic fate. (Molecular Connection Vol. 19 No. 1, Spring 2000, pp 12-13)

This study describes how Jing Wang and Kal Ramnarayan of Structural Bioinformatics, Inc. (San Diego, CA) developed a computational method for determining which compounds are most like drugs. (Molecular Connection Vol. 19 No. 1, Spring 2000, pp 16-17)

Planning a successful migration: moving molecule databases to data cartridge format in MDL Direct (Molecular Connection Vol. 19 No. 2, Winter 2000, pp 14-17)

Working with focused libraries: Using MDL Software and Argonaut Instrumentation (Molecular Connection Vol. 19 No. 2, Winter 2000, pp 6-9)

BASF Introduces an ISIS-based Reaction Management System. (Molecular Connection Vol. 18 No. 4, Fall 1999, pp 10-11, 23)